Replies to post #124665 on Biotech Values

[jq1234]

Any thoughts on this new strategy or much to do about nothing? It seems either a strategy change or perhaps insight into the challenges of their present discussions with partners for the FoB program who may be playing hardball?

Nowhere did they imply they wanted to go alone. Read the portion you quoted:

We also have the ability to potentially co-invest which actually leaves us the potential to actually get a higher share of the revenues of those products and ultimate success. So, we think we need to use it judiciously but we still think we need partnerships.

[DewDiligence]

It seems either a strategy change or perhaps insight into the challenges of their present discussions with partners for the FoB program who may be playing hardball?

There is a no change in MNTA’s FoB strategy per se, but there’s a change in what MNTA is seeking from an FoB partner. Thanks to MNTA’s $300M+ cash balance and strong cash flow from operations, MNTA no longer needs an FoB partnership for the partner’s cash; MNTA does, however, need an FoB partnership for the partner’s commercialization expertise. This makes the FoB-partnership negotiations rather different than they would be if MNTA were primarily looking for cash. Regards, Dew